|1.||Horiuchi, Yoshinobu: 5 articles (09/2014 - 03/2009)|
|2.||Ochiai, Masaki: 4 articles (09/2014 - 03/2009)|
|3.||Schuerman, Lode: 4 articles (12/2011 - 10/2004)|
|4.||Jacquet, Jeanne-Marie: 4 articles (01/2010 - 10/2007)|
|5.||Valenta, Rudolf: 3 articles (08/2012 - 08/2002)|
|6.||Rusinak, Donna: 3 articles (05/2012 - 06/2009)|
|7.||Lieu, Tracy A: 3 articles (05/2012 - 06/2009)|
|8.||Anemona, A: 3 articles (04/2010 - 02/2001)|
|9.||Heininger, Ulrich: 3 articles (01/2008 - 07/2005)|
|10.||Kemmeren, Jeanet M: 2 articles (08/2015 - 06/2011)|
|1.||Whooping Cough (Pertussis)
10/25/2013 - "Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience."
10/25/2013 - "This monocomponent aP vaccine can be used in combination vaccines for primary and booster vaccination against pertussis in all age groups and is an important tool for successful pertussis control. "
01/01/2012 - "A need for careful evaluation of endotoxin contents in acellular pertussis-based combination vaccines."
06/10/2011 - "However, for primary and booster vaccinations together, immunisation with acellular pertussis combination vaccines results in fewer adverse events than vaccination of whole cell combination vaccines. "
04/01/2010 - "monographs for acellular pertussis-based combination vaccines in order to alleviate animal suffering (in application of the 3Rs principle). "
10/01/1990 - "[The determination of the protective potency of the diphtheria component in combined vaccines by the indirect hemagglutination (IHA) method]."
01/01/1986 - "A mouse model is presented to estimate the potency of the diphtheria component in combined vaccines. "
01/01/1986 - "A mouse model to estimate the potency of the diphtheria component in combined vaccines."
07/01/2013 - "The risk in the 6-week interval compared to the prior 12 months for tetanus diphtheria combination, 23-valent pneumococcal polysaccharide, and for all vaccines combined was 1.4 (95% CI, .3-4.5), 0.7 (95% CI, .1-2.9), and 1.3 (95% CI, .8-2.3), respectively. "
01/01/1999 - "The ultimate goal of this project was to determine whether serological assays can be used for testing combined vaccines, particularly for tetanus and diphtheria components, using sera from the same animals."
01/01/2013 - "In this study, we investigated the effect of HibT containing combination vaccines on anti-tetanus potencies by using animal models (mouse, guinea pig, and rat). "
12/01/2012 - "In adults with a tetanus-prone injury, combined vaccines such as Tdap-IPV (REPEVAX®) can boost immunity against several diseases simultaneously. "
05/01/2012 - "Immunogenicity of a Haemophilus influenzae type b-tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey."
11/30/1980 - "In tetanus prevention it is of basic importance to establish and maintain active immunity by means of combined vaccines. "
08/01/1974 - "[The duration and intensity of antitoxic tetanus immunity in children inoculated with combined vaccines]."
01/01/2012 - "The concept of prevention (cancer as danger, future health, and trust in vaccines) combined with pragmatic factors (no cost, available at school) and the credibility of the offer (information in the media, recommendation of respected authority figure) were central to motivations that led parents to decide to vaccinate their daughters. "
11/15/2004 - "The data showed the superior therapeutic efficiency of combined vaccines containing apoptotic tumor cells. "
09/15/2001 - "Significant increase in CTL activity was demonstrated after mice were immunized with the combined vaccines and all mice were protected from D2F2/E2 tumor growth. "
10/29/2008 - "In the current study, we characterized the therapeutic effect of tumor cell-based vaccines combined with the adjuvant, alpha-galactosylceramide (alpha-GalCer) using two different mouse models. "
07/01/2010 - "Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression."
04/01/2008 - "Larger DTPw-based combination vaccines facilitate high coverage and protection against other childhood pathogens, such as hepatitis B (HBV) and Haemophilus influenzae type b (Hib). "
06/01/2003 - "Lastly the combination vaccines of Hib with IPV, DPwT/DPaT, and Hepatitis B are safe and effective and should be encouraged to improve the compliance. "
04/30/2010 - "This highly immunogenic hepatitis B candidate vaccine was selected for further investigation as a component of new pediatric combination vaccines."
10/01/2008 - "Recruited subjects were randomized to receive three doses of either of the two DTPw-Hepatitis B combination vaccines as per the EPI schedule. "
10/01/2008 - "Immunogenicity and safety of DTPw-hepatitis B combined vaccines."
|5.||Pentetic Acid (DTPA)
|6.||Immunologic Factors (Immunomodulators)
|8.||Japanese Encephalitis Vaccines
|9.||Polymeric Immunoglobulin Receptors (Polymeric Immunoglobulin Receptor)
|5.||Immunologic Contraception (Immunocontraception)